ArticleFrontiers in immunology2026
Immunological profiling and treatment patterns of primary Sjögren's disease patients with concomitant rheumatoid arthritis: a retrospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The coexistence of primary Sjögren's disease (pSS) and rheumatoid arthritis (RA) is not uncommon, but its immunological characteristics and treatment patterns remain poorly defined. This study aimed to compare the immune profiles and therapeutic strategies between pSS patients with and without RA overlap. Methods: A total of 148 patients with pSS were retrospectively enrolled, including 89 without RA and 59 with concomitant RA. Demographic characteristics, inflammatory markers, cytokines, lymphocyte subsets, autoantibodies, and treatment regimens were analysed. Logistic regression and ROC analyses were performed to identify markers associated with pSS+RA overlap group. Results: Compared with the non-RA group, patients in the overlap group had longer disease duration and higher ESR levels. IL-6, IL-17, and IL-8 levels were significantly elevated, accompanied by increased CD4 Conclusion: Patients with pSS and concomitant RA exhibit an immune profile characterized by IL-6 pathway activation, T-cell predominance, and altered B-cell responses, closely resembling RA immunopathology. These findings provide insights into autoimmune overlap syndromes and support IL-6 as a potential therapeutic target in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.